Evaluating the potential for immune escape: how likely is an antibody to protect against a specific SARS-CoV-2 variant?
out of 5 stars
24 May 2024 | Contributor(s): Allyson Sterling, Erica Lannan, Sandra Porter | doi:10.25334/Q7KG-5V20
Commercial antibodies to the SARS-CoV-2 spike protein have been successfully used to treat people with COVID-19. Unfortunately, as the SARS-CoV-2 virus evolves, new variants have appeared that can escape some of these antibodies. In fact, many commercial antibodies that received Emergency Use...